TY - JOUR

T1 - Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes

AU - Schmidt, Signe

AU - Frandsen, Christian S.

AU - Dejgaard, Thomas F.

AU - Vistisen, Dorte

AU - Halldorsson, Thorhallur

AU - Olsen, Sjurdur F.

AU - Jensen, Jens-Erik B.

AU - Madsbad, Sten

AU - Andersen, Henrik U.

AU - Nørgaard, Kirsten

PY - 2022

Y1 - 2022

N2 - AimsTo present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss.Materials and methodsA 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake.ResultsTotal fat and lean body mass decreased in liraglutide-treated participants (fat mass −4.6 kg [95% confidence interval {CI} −5.7; −3.5], P < 0.001; lean mass −2.5 kg [95% CI −3.2;-1.7], P < 0.001), but remained stable in placebo-treated participants (fat mass −0.3 kg [95% CI −1.3;0.8], P = 0.604; lean mass 0.0 kg [95% CI −0.7;0.7]; P = 0.965 [between-group P values <0.001]). Participants reduced their energy intake numerically more in the liraglutide arm (−1.1 MJ [95% CI −2.0;-0.02], P = 0.02) than in the placebo arm (−0.9 MJ [95% CI −2.0;0.1], P = 0.22), but the between-group difference was statistically insignificant (P = 0.42). However, energy derived from added sugars decreased by 27% in the liraglutide arm compared with an increase of 14% in the placebo arm (P = 0.004).ConclusionsLiraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.

AB - AimsTo present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss.Materials and methodsA 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake.ResultsTotal fat and lean body mass decreased in liraglutide-treated participants (fat mass −4.6 kg [95% confidence interval {CI} −5.7; −3.5], P < 0.001; lean mass −2.5 kg [95% CI −3.2;-1.7], P < 0.001), but remained stable in placebo-treated participants (fat mass −0.3 kg [95% CI −1.3;0.8], P = 0.604; lean mass 0.0 kg [95% CI −0.7;0.7]; P = 0.965 [between-group P values <0.001]). Participants reduced their energy intake numerically more in the liraglutide arm (−1.1 MJ [95% CI −2.0;-0.02], P = 0.02) than in the placebo arm (−0.9 MJ [95% CI −2.0;0.1], P = 0.22), but the between-group difference was statistically insignificant (P = 0.42). However, energy derived from added sugars decreased by 27% in the liraglutide arm compared with an increase of 14% in the placebo arm (P = 0.004).ConclusionsLiraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.

KW - body composition

KW - food frequency

KW - insulin pump therapy

KW - liraglutide

KW - type 1 diabetes

KW - weight loss

U2 - 10.1111/dom.14567

DO - 10.1111/dom.14567

M3 - Journal article

C2 - 34595827

VL - 24

SP - 212

EP - 220

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -